Is JW (Cayman) Therapeutics (HKG:2126) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. Importantly, JW (Cayman) Therapeutics Co. Ltd (HKG:2126) does carry debt. But is this debt a concern to shareholders?

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

When Is Debt Dangerous?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

What Is JW (Cayman) Therapeutics's Debt?

As you can see below, JW (Cayman) Therapeutics had CN¥339.8m of debt, at June 2025, which is about the same as the year before. You can click the chart for greater detail. But it also has CN¥646.9m in cash to offset that, meaning it has CN¥307.1m net cash.

A Look At JW (Cayman) Therapeutics' Liabilities

We can see from the most recent balance sheet that JW (Cayman) Therapeutics had liabilities of CN¥470.3m falling due within a year, and liabilities of CN¥40.5m due beyond that. Offsetting these obligations, it had cash of CN¥646.9m as well as receivables valued at CN¥28.7m due within 12 months. So it can boast CN¥164.8m more liquid assets than total liabilities.

This surplus suggests that JW (Cayman) Therapeutics has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Succinctly put, JW (Cayman) Therapeutics boasts net cash, so it's fair to say it does not have a heavy debt load! There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine JW (Cayman) Therapeutics's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

See our latest analysis for JW (Cayman) Therapeutics

Over 12 months, JW (Cayman) Therapeutics reported revenue of CN¥178m, which is a gain of 2.8%, although it did not report any earnings before interest and tax. We usually like to see faster growth from unprofitable companies, but each to their own.

So How Risky Is JW (Cayman) Therapeutics?

We have no doubt that loss making companies are, in general, riskier than profitable ones. And we do note that JW (Cayman) Therapeutics had an earnings before interest and tax (EBIT) loss, over the last year. And over the same period it saw negative free cash outflow of CN¥349m and booked a CN¥618m accounting loss. However, it has net cash of CN¥307.1m, so it has a bit of time before it will need more capital. Even though its balance sheet seems sufficiently liquid, debt always makes us a little nervous if a company doesn't produce free cash flow regularly. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. For example, we've discovered 2 warning signs for JW (Cayman) Therapeutics (1 is a bit unpleasant!) that you should be aware of before investing here.

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.